

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**CANbridge Pharmaceuticals Inc.**  
**北海康成製藥有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1228)**

**(1) RESIGNATION OF NON-EXECUTIVE DIRECTOR;  
(2) CHANGE IN COMPOSITION OF BOARD COMMITTEE; AND  
(3) WITHDRAWAL OF ORDINARY RESOLUTION NUMBER 2(i) AT THE AGM**

**RESIGNATION OF NON-EXECUTIVE DIRECTOR**

The board (the “**Board**”) of directors (each, a “**Director**” and collectively, the “**Directors**”) of CANbridge Pharmaceuticals Inc. (the “**Company**”) hereby announces that Dr. Fangxin Li (“**Dr. Li**”) has resigned as a non-executive Director and a member of the remuneration committee of the Board (the “**Remuneration Committee**”) with effect from June 25, 2025 due to changes in his work arrangements.

Dr. Li has confirmed that he had no disagreement with the Board and there were no matters relating to his resignation that should be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited.

The Board would like to take this opportunity to express its sincere gratitude to Dr. Li for his valuable contribution to the Company during his tenure of office.

**CHANGE IN COMPOSITION OF THE REMUNERATION COMMITTEE**

Pursuant to the terms of reference of the Remuneration Committee, the Remuneration Committee shall comprise of not less than three members. Following the resignation of Dr. Li as a committee member of the Remuneration Committee, the Remuneration Committee comprises only two members (who are independent non-executive Directors), and as a result, the number of members of the Remuneration Committee falls below three, and no longer meets, the composition requirements as set out in the terms of reference of the Remuneration Committee.

The Board is in the process of identifying a suitable candidate to fill the aforementioned vacancy and will use its best endeavors to ensure that a suitable candidate is appointed as soon as practicable to re-comply with the relevant requirement of the terms of reference of the Remuneration Committee. The Company will make further announcement(s) as and when appropriate.

## **WITHDRAWAL OF ORDINARY RESOLUTION NUMBER 2(i) AT THE AGM**

Reference is made to the notice of annual general meeting of the Company dated June 6, 2025 (the “**AGM Notice**”), the circular of the Company dated June 6, 2025 (the “**Circular**”) and the proxy form (the “**Proxy Form**”) for the annual general meeting of the Company to be held virtually at 9:00 a.m. on Friday, June 27, 2025 (the “**AGM**”) in relation to, inter alia, the retirement by rotation, and the proposed re-election, of Dr. Li (the “**Proposed Re-election**”) at the AGM.

Forthwith upon the resignation of Dr. Li with effect from June 25, 2025, the proposed ordinary resolution numbered 2(i) as set out in the AGM Notice in respect of the Proposed Re-election will be withdrawn and will not be put forward for consideration and approval by the shareholders of the Company at the AGM.

Save for the aforementioned withdrawal of the proposed ordinary resolution numbered 2(i), all information and contents (including but not limited to the date and time for holding the AGM) as set out in the AGM Notice, the Circular and the Proxy Form remain unchanged. The Proxy Form shall remain valid except that no poll will be conducted or counted for the proposed ordinary resolution numbered 2(i) at the AGM.

By Order of the Board  
**CANbridge Pharmaceuticals Inc.**  
北海康成製藥有限公司  
**Dr. James Qun Xue**  
*Chairman*

Hong Kong, June 25, 2025

*As of the date of this announcement, the Board comprises Dr. James Qun Xue as executive Director, and Dr. Richard James Gregory, Mr. James Arthur Geraghty, Mr. Peng Kuan Chan and Dr. Lan Hu as independent non-executive Directors.*